 |
MBBS (S'pore), MHS (USA), MMED (Int Med), MRCP (UK)
Consultant, Cardiac Department, NUHCS |
Dr Mark Chan is a practicing cardiologist at the National University Hospital, Singapore, and a clinical instructor at the Yong Loo Lin School of Medicine, Singapore. Dr Chan obtained his Master of the Royal College of Physicians (UK) diploma in 2002, and completed his cardiology training at the National University Hospital, Singapore in 2006.
He subsequently spent two years doing clinical-translational research at the Duke Clinical Research Institute, during which he served as a co-chief fellow, and graduated with a Master of Health Science degree from Duke University in 2008. He then spent another 18 months at the Montreal Heart Institute doing a combined fellowship in interventional cardiology and platelet biology.
He has authored or co-authored more than 30 papers in peer-reviewed journals, including tier 1 journals such as Circulation, and has presented more than 20 abstracts at international scientific meetings. He has been the principal investigator of multiple large outcome studies in acute coronary syndromes, the co-principal investigator of two phase I studies on a novel factor IX aptamer-antidote anticoagulant system and now serves on the steering committee of the international phase III TRILOGY-ACS study.
Presently, he is the principal investigator of the following studies: an NMRC-funded study investigating platelet gene expression predictors of clopidogrel resistance, a study profiling the human metabolome in ischemia-reperfusion, and a study to validate the GRACE risk score in a nation-wide registry of patients with acute coronary syndromes. He presently supervises the NUHCS cardiovascular research thrombosis program and the high-risk post-ST elevation myocardial infarction (STEMI) clinic.
Specialty Interest(s):
- Interventional Cardiology, platelet biology and pharmacology, metabolomics, risk stratification and outcomes in Acute Coronary Syndromes.
|
Specializes in Diseases and Conditions:
- Antiplatelet resistance
- Stent thrombosis
- High risk post-STEMI patients
- Patients with elevated peri-procedural bleeding risk
|
Professional Highlights
-
-
Interview by Nature Cardiology Reviews on Chan et al, Circulation 2009;119:3110-3117
-
Research highlights review at www.cardiosource.com on Chan et al, JACC CI 2008;1;369-378.
-
Member, International editorial board, Journal of the Brazilian Society of Internal Medicine, 2007-present day
-
Member, International editorial board, Brazilian national journal of intervention cardiology. 2009-present day
Awards & Honors
-
Dean’s list Final Professional Examination MBBS 1998-1999 awarded by Dean, Faculty of Medicine, National University of Singapore
-
Interview by Nature Cardiology Reviews on Chan et al, Circulation 2009;119:3110-3117
-
SARS courage medal 2003 for valour and selfless dedication awarded by President S. R. Nathan, Patron-in-chief, The Courage Fund
-
National Healthcare Group best clinical tutor award 2003-2004 awarded by the National Healthcare Group college
-
Young Investigator’s Award (clinical science and overall winner) 1st prize Singapore Cardiac Society 17th Annual Scientific Meeting awarded by the Singapore Cardiac Society
-
Ralph Snyderman Award 2007 for promising young investigators awarded by ex-chancellor Duke School of Medicine
-
Medical Research Fellowship award 2006-2008 awarded by National Medical Research Council, Singapore
-
Health Manpower Development Programme Fellowship award 2008-2009 awarded by Ministry of Health, Singapore
-
Young Investigator’s Award (clinical science and overall winner) 3rd prize Singapore Cardiac Society 21th Annual Scientific Meeting awarded by the Singapore Cardiac Society
Professional Memberships
-
Member, Singapore Medical Association, 1999-present day
-
Member, Royal College of Physicians, United Kingdom, 2002-present day
-
Member, American Heart Association, 2006-present day
-
Member, American College of Cardiology, 2006-present day
-
Member, College des Medicines du Quebec, 2008-present day
Selected Publications
1. Mark Y. Chan, Lena J. Sun, L. Kristin Newby, Linda K. Shaw, Min Lin, Eric D. Peterson, Robert M Califf, David F. Kong, and Matthew T. Roe. Long-Term Mortality of Patients Undergoing Cardiac Catheterization for ST-elevation and Non ST-elevation Myocardial Infarction. Circulation 2009;119:3110-3117.
2. Mark Y. Chan, Mauricio G. Cohen, Christopher K. Dyke, Shelley K. Myles, Laura G. Aberle, Min Lin, Nicholas Chronos, Chiara Melloni, John H. Alexander, Robert A. Harrington, Ross M. Tonkens, James Walden, Steven R. Steinhubl, Ian C. Gilchrist, Neal S. Kleiman, David A. Vorchheimer, Richard C. Becker, and Christopher P. Rusconi: A Phase 1b Randomized Study of Antidote-Controlled Modulation of Factor IXa Activity in Patients with Stable Coronary Artery Disease. Circulation. 2008;117:2865-2874.
3. Mark Y. Chan, Christopher P. Rusconi, John H. Alexander, Ross M. Tonkens, Robert A. Harrington, and Richard C. Becker: A randomized, repeat dose, pharmacodynamic, and safety study of an antidote-controlled factor IXa inhibitor. J Thromb Haemost. 2008 May;6(5):789-96.
4. Mark Y. Chan, Kenneth W. Mahaffey, Lena J. Sun, Karen S. Pieper, Harvey D. White, Philip E. Aylward, James J. Ferguson, Robert M. Califf, and Matthew T. Roe. Prevalence, Predictors, and Impact of Conservative Medical Management for Patients with Non–ST-Segment Elevation Acute Coronary Syndromes Who Have Angiographically Documented Significant Coronary Disease, J Am Coll Cardiol Cardiovasc Interventions 2008;1;369-378.
5. Mark Y Chan, Felicita Andreotti, Richard C. Becker: Hypercoagulable States in Cardiovascular Disease. Circulation 2008;118;2286-2297.
For more of his publications, read here.
Back to Top
